ABCL News and Press, AbCellera Biologics Inc. From 06/26/22

Stanley Druckenmiller’s 13F portfolio value decreased from $2.93B to $2.31B this quarter. Duquesne added Teck Resources and Coterra Energy while dropping Alphabet, Carvana, and Palo Alto Networks. They also added a large short position in S&P 500 index through Puts. The...

Berenberg has started Denali Therapeutics (NASDAQ:DNLI) with a buy rating saying that the central nervous system ("CNS")-focused company has technology making it possible to get drugs directly into the brain. The firm has a $39 price target (~43% upside based on Wednesday's close). Analyst Ca...

AbCellera Biologics (NASDAQ:ABCL) has disclosed a ~$480K share purchase by 10% owner Thermopylae Holdings. Thermopylae purchased 64,545 shares of the company's common stock at $7.44 - $7.55 price range on June 06, 2022. Shares of the biotech firm is up 10% currently, but has dropped...

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

Gainers: Warner Bros. Discovery (WBD) +16%. GitLab (GTLB) +10%. BuzzFeed (BZFD) +6%. Kingsoft Cloud Holdings Limited (KC) +5%. Allbirds (BIRD) +5%. Losers: Weatherford International  (WFRD) -10%. Sierra Wireless (SWIR) -5%. HashiCorp (HCP) -4%. Agora (API) -3%. AbCellera Biolog...

AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform,...

The U.S. FDA declined to approve an Emergency Use Authorization (EUA) request to use the antidepressant Luvox (fluvoxamine) as a COVID-19 therapy stating the treatment benefit of the drug "was not persuasive when focusing on clinically meaningful outcomes." The request was filed in Decem...

Shares of contract drug developer AbCellera Biologics (NASDAQ: ABCL) are down 10% as of 12:04 p.m. ET today, according to data from S&P Global Market Intelligence , following Piper Sandler's lowered price target despite a seemingly strong earnings report. For the three-m...

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q1 2022 Earnings Call May 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q1 2022 Earnings Call Transcript ...

AbCellera Biologics Inc. (ABCL) Q1 2022 Results Conference Call May 10, 2022 05:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fau...